Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGER | Q15109 | 3/20 | 0.55 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.55 |
| ▸ | CTSD | P07339 | 1/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL736914 | 0.93 | AGER (0.50) | AGERMTNR1ACHRM2CHRM3CTSD | |
| SCHEMBL736913 | 0.93 | AGER (0.50) | AGERMTNR1ACHRM2CHRM3CTSD | |
| SCHEMBL738277 | 0.91 | MC4R (0.54) | AGERMTNR1ACHRM2CHRM3CTSD | |
| SCHEMBL77425 | 0.91 | MC4R (0.54) | AGERMTNR1ACHRM2CHRM3CTSD | |
| SCHEMBL2814615 | 0.91 | AGER (0.67) | AGERMTNR1ACHRM2CHRM3CTSD | |
| SCHEMBL3811903 | 0.89 | DCUN1D1 (0.58) | AGERMTNR1ACHRM2CHRM3CTSD | |
| SCHEMBL2400009 | 0.88 | OPRM1 (0.51) | AGERMTNR1ACHRM2CHRM3CTSD | |
| SCHEMBL13275447 | 0.88 | OPRM1 (0.51) | AGERMTNR1ACHRM2CHRM3CTSD | |
| SCHEMBL862071 | 0.88 | AGER (0.47) | AGERMTNR1ACHRM2CHRM3CTSD | |
| SCHEMBL2400012 | 0.88 | OPRM1 (0.51) | AGERMTNR1ACHRM2CHRM3CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101146530-B | 3, 4-substituted pyrrolidine derivatives for the treatment of hypertension | NOVARTIS AG | 2011-05-18 | — | — | CN | claimed |
| EP-1863477-B1 | 3,4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION | NOVARTIS AG (CH) | 2010-11-03 | — | — | EP | claimed |
| US-7807709-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-10-05 | — | — | US | claimed |
| US-20080194549-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-08-14 | — | — | US | claimed |
| CN-101146530-A | 3, 4-substituted pyrrolidine derivatives for the treatment of hypertension | NOVARTIS AG (CH) | 2008-03-19 | — | — | CN | claimed |
| EP-1863477-A1 | 3,4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION | Novartis AG (CH) | 2007-12-12 | — | — | EP | claimed |
| WO-2006100036-A1 | 3, 4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION | NOVARTIS AG (CH) | 2006-09-28 | — | — | WO | claimed |
| WO-2006100036-A1 | 3, 4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION | NOVARTIS AG (CH) | 2006-09-28 | — | — | WO | disclosed |
| US-4309517-A | LIVING ALKALI METAL-TERMINATED | PHILLIPS PETROLEUM COMPANY (US) | 1982-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194549-A1 | Organic Compounds | REN, ACE, OTC | AGER 543/4885MTNR1A 2326/4885CHRM2 4261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.